Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from National Institutes of Health

We need to talk about "mild Covid" — and why it sucks

Early in the pandemic, doctors defined mild, moderate, and severe Covid. Two and a half years later, do they still make sense?

Inverse

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Benzinga

Cells become zombies when the ends of their chromosomes are damaged – a tactic both helpful and harmful for health

The Research Brief is a short take about interesting academic work.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Biomedical grantmakers' diversity push gains new momentum

The Howard Hughes Medical Institute, one of the nation’s wealthiest philanthropies, announced a $1.5 billion effort designed to help scientists of color advance in their careers

The Independent UK

Efficacy Of Pfizer's Paxlovid COVID Drug Crashes, According To New NIH-Funded Study

A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.

Benzinga

Anthony Fauci tests positive for Covid with mild symptoms

Biden’s chief medical adviser received two booster shots and is working from home, says National Institutes of Health

The Guardian - US

Why opting out of opioids can be dangerous in the operating room

Currently, patients in seven states can tell their physicians they don’t want to be treated with opioids in any health care setting, even during surgery. While unnecessary opioid exposure is a big reason behind the opioid epidemic in the U.S., we believe that non-opioid directives that allow patients to opt…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Former longtime Illinois US Rep. John E. Porter dies at 87

Former Illinois U.S. Rep. John E

The Independent UK

Researchers find that 2 drugs reduced COVID-19 deaths

ST. LOUIS — The National Institutes of Health released early results on of a trial involving Washington University, showing that two anti-inflammatory drugs reduced the risk of death in patients with severe COVID-19.

St. Louis Post-Dispatch

The lasting consequences of school shootings on the students who survive them

As the U.S. reels from another school shooting, much of the public discussion has centered on the lives lost: 19 children and two adults. Indeed, the massacre at Robb Elementary School in Uvalde, Texas is the second deadliest such incident on record, after the shooting at Sandy Hook Elementary School…

The Conversation

Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?

Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Zyesami (aviptadil) should cease due to futility. Aviptadil was the sole remaining investigational medicine in ACTIV-3b targeted at critical-ill COVID-19 patients. ACTIV-3b study evaluated Zyesami and Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir)…

Benzinga

Zinc is a metal essential to life – scientists have discovered a protein that helps keep cells alive when zinc levels are low

All living things, including people, need zinc in their diets. Getting too little of this essential metal can impair growth and cause immune dysfunction, neurological disorders and cancer. Unfortunately, over 17% of the world’s population is at risk for zinc deficiency. The World Health Organization considers this kind of micronutrient-related…

The Conversation

Just how accurate are rapid antigen tests? Two testing experts explain the latest data

As of May 2022, the U.S. is experiencing another uptick in the number of COVID-19 cases. High rates of infection in Europe and Asia, along with the continued emergence of new sub-variants, such as omicron BA.4 and BA.5, raise concerns that another surge could be on the way.

The Conversation

How COVID vaccines have boosted the development of an HIV vaccine

During the pandemic scientists launched a vaccine in record-breaking time. Their successful use of mRNA technology could lead to progress in the decades-long effort for an HIV inoculation.

WEKU

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Senators Cory Booker And Brian Schatz Call On Federal Agencies To Research Psychedelics

Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the FDA whom they called on to study the therapeutic potent

The Conversation

When it comes to the rarest of diseases, the diagnosis isn't the answer – it's just the starting point

“Mr. and Mrs. Smith, we finally have an answer for you.” The couple, whose real names we are protecting for privacy, looked at me anxiously. I had been evaluating their young daughter, Sally, in my role as a medical geneticist at the Children’s Hospital at Montefiore in the Bronx, a…

Benzinga

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Tribune News Service

Gilbert Gottfried had myotonic dystrophy before his death. What is the rare disease?

Comedian Gilbert Gottfried died on Tuesday after a long illness, his family announced.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Philadelphia Inquirer

Q&A: Penn ethicist Zeke Emanuel has another life as a venture capitalist

Ezekiel Emanuel chairs the department of medical ethics and health policy at the University of Pennsylvania. He started the bioethics department at the National Institutes of Health, helped shape U.S. health-care policy as a senior aide in the Obama administration, served on President Joe Biden's COVID-19 task force, and advocates…

The Conversation

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Discovering new ways to use existing drugs can come about intentionally or by chance.

The Conversation

New data-sharing requirements from the National Institutes of Health are a big step toward more open science – and potentially higher-quality research

Starting on Jan. 25, 2023, many of the 2,500 institutions and 300,000 researchers that the U.S. National Institutes of Health supports will need to provide a formal, detailed plan for publicly sharing the data generated by their research. For many in the scientific community, this new NIH Data Management and…

Tribune News Service

COVID’s ‘silver lining’: Research breakthroughs for chronic disease, cancer and the common flu

The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases.

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Centers for Disease Control and Prevention

University of California

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.